Cognition Therapeutics Statistics
Share Statistics
Cognition Therapeutics has 41.55M shares outstanding. The number of shares has increased by 32.4% in one year.
| Shares Outstanding | 41.55M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.19% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 35.21M |
| Failed to Deliver (FTD) Shares | 98 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 815.70K, so 1.96% of the outstanding shares have been sold short.
| Short Interest | 815.70K |
| Short % of Shares Out | 1.96% |
| Short % of Float | 2.33% |
| Short Ratio (days to cover) | 1.07 |
Valuation Ratios
The PE ratio is -2.15 and the forward PE ratio is -0.78.
| PE Ratio | -2.15 |
| Forward PE | -0.78 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 2.27 |
| P/FCF Ratio | -3.43 |
| PEG Ratio | n/a |
Enterprise Valuation
Cognition Therapeutics Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 3.37, with a Debt / Equity ratio of 0.03.
| Current Ratio | 3.37 |
| Quick Ratio | 3.37 |
| Debt / Equity | 0.03 |
| Total Debt / Capitalization | 2.76 |
| Cash Flow / Debt | -23.08 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -1.05% and return on capital (ROIC) is -197.28%.
| Return on Equity (ROE) | -1.05% |
| Return on Assets (ROA) | -0.73% |
| Return on Capital (ROIC) | -197.28% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.03M |
| Employee Count | 25 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -75.98% in the last 52 weeks. The beta is 1.33, so Cognition Therapeutics 's price volatility has been higher than the market average.
| Beta | 1.33 |
| 52-Week Price Change | -75.98% |
| 50-Day Moving Average | 0.46 |
| 200-Day Moving Average | 1.27 |
| Relative Strength Index (RSI) | 54.05 |
| Average Volume (20 Days) | 1.54M |
Income Statement
In the last 12 months, Cognition Therapeutics had revenue of $0 and earned -$25.79M in profits. Earnings per share was $-0.86.
| Revenue | 0 |
| Gross Profit | -252.00K |
| Operating Income | -50.72M |
| Net Income | -25.79M |
| EBITDA | -25.51M |
| EBIT | - |
| Earnings Per Share (EPS) | -0.86 |
Balance Sheet
The company has $29.92M in cash and $1.24M in debt, giving a net cash position of $28.68M.
| Cash & Cash Equivalents | 29.92M |
| Total Debt | 1.24M |
| Net Cash | 28.68M |
| Retained Earnings | -141.19M |
| Total Assets | 27.58M |
| Working Capital | 14.13M |
Cash Flow
In the last 12 months, operating cash flow was -$16.02M and capital expenditures -$147.00K, giving a free cash flow of -$16.16M.
| Operating Cash Flow | -16.02M |
| Capital Expenditures | -147.00K |
| Free Cash Flow | -16.16M |
| FCF Per Share | -0.54 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
CGTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -175.51% |
| FCF Yield | -80.09% |
Analyst Forecast
The average price target for CGTX is $9, which is 1736.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $9 |
| Price Target Difference | 1736.7% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Scores
| Altman Z-Score | -10.99 |
| Piotroski F-Score | 3 |